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ABSTRACT OF THE DISSERTATION 
 
A platform for investigating immune checkpoint-mediated changes in metabolism 
by 
Nicolaos Jay Palaskas 
Doctor of Philosophy in Molecular, Cellular, and Integrative Physiology 
University of California, Los Angeles, 2017 
Professor Thomas G. Graeber, Chair 
 
There is a growing interest in metabolomic profiling of immune cells, as there is accumulating 
evidence that metabolism influences immune cell function and fate decisions.  The non-adherent 
nature of these cells presents certain challenges not factored into extraction protocols developed 
for adherent cells.  Here, we present a method developed for metabolite extraction from human 
T-cells that emphasizes simplicity and economy.  We apply this method to profile the metabolic 
changes effected by in-vitro programmed cell death 1 receptor (PDCD1/PD-1) immune 
checkpoint engagement by liquid chromatography and mass spectrometry.  We demonstrate that 
we can efficiently confirm the known reduction in aerobic glycolysis and glutaminolysis that 
accompanies PD-1 signaling and extend this by showing a block in de novo nucleoside 
phosphate biosynthesis. 
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CHAPTER 1 
Introduction 
Immune therapies for cancer have met unprecedented success in the recent years1.  T-cells are 
central to anti-tumor immune surveillance2 and several approaches with varying degrees of 
success have been used to stimulate them to attack tumors. These methods include vaccines3, 
bispecific antibodies (BiTEs)4,5, and adoptive cell transfer (ACT) with innate or engineered 
tumor recognition surface receptors6–8.   
Immune checkpoint blockade targeting Programmed Cell Death 1 (PDCD1/PD-1) and its ligand 
CD274  molecule (more commonly referred to as PD-L1) has captured the lion’s share of 
attention due to the long term responses in the metastatic setting with limited toxicities9,10.  T-
cells can often be found at the tumor margin and infiltrate and proliferate within the tumor upon 
successful immune checkpoint blockade11.  A critical shortcoming, however, is that some 
patients display de novo refractoriness, despite high mutational burden and predicted 
immunogenicity12.  Often, the tumors of these patients will either not have inhibitory ligand 
expression, as measured by immunohistochemical methods, or will not have an appreciable 
immune infiltrate at the tumor margin11.  This suggests 1) other immune suppression mechanisms 
or 2) a more profound immune exhaustion, which may even require adoptive T-cell transfer 
(ACT) for immune checkpoint blockade to be effective.  As the experience with checkpoint 
inhibitor therapy matures, cases of acquired resistance are a growing clinical challenge12,13.  
Furthermore, recent data suggests that PD-1 signaling must be targeted with caution, as PD-1 is 
necessary to prevent T-cell terminal differentiation and exhaustion in a murine model of chronic 
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viral infection14.   Thus, a better understanding of T-cell function and fate decisions in these 
contexts is needed. 
There is mounting evidence for the regulatory role of metabolism in T-cell effector function and 
determination of cell fate, giving rise to the concept of metabolic checkpoints in T-cells15.  It is 
known that T-cell metabolism is highly regulated, with a requirement for constant cytokine 
signaling to maintain homeostasis and basal proliferation.  Upon activation the cells undergo 
drastic metabolic reprogramming.  They switch metabolic prominence from full catabolism of 
glucose via the Krebs cycle and oxidative phosphorylation (OXPHOS) to aerobic glycolysis, 
resulting in high levels of lactate production and a redirection of glucose to the pentose 
phosphate shunt, very much akin to the Warburg effect in cancer.  Immune checkpoint signaling 
can alter the capacity of the cells to fully maintain this metabolic program16,17.  Beyond the 
common viewpoint of signaling regulating metabolic activity, there are recent examples of the 
direct effect of nutrient restriction on effector function, suggesting cancer can escape immune 
surveillance by out-competing effector cells for key nutrients18–20, thus raising the potential for 
metabolism- and nutrient-based  therapies. 
By understanding the effect of metabolism on lymphocyte effector functions and fate decisions 
one can then seek ways to manipulate and direct those decisions to achieve more robust and long 
lasting immune-based therapies.  Already, there are such proof of principle studies in the context 
of adoptive cell transfer in murine models21–23.  Additionally, the similarities of the activated T-
cell phenotype to cancer has led some to propose T-cell metabolic reprogramming as a model for 
the study of the Warburg phenomenon and carcinogenesis24.  Yet, from a therapeutic standpoint, 
exposing the metabolic dissimilarities between cancer and immune metabolism is desirable, as 
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one would want to exploit such targets to inhibit tumor cells while promoting immune cell 
function.   
Using unbiased methods to explore metabolic checkpoints in T-cells holds promise to uncover 
these targets.  Mass spectrometry is an unbiased technology that has radically changed the field 
by providing the ability to do systems-level analyses of metabolism25.  It has allowed for the 
discovery of new tumor-associated metabolites and changes in metabolic pathway fluxes that 
result from aberrant expression of normal proteins or cancer-related mutations.  The production 
of the “oncometabolite” 2-hydroxyglutarate by mutant isocitrate dehydrogenase in gliomas and 
the increased production of nucleotides as a consequence of expression of the M2 isoform of the 
glycolytic enzyme pyruvate kinase (PKM2) are two notable examples26,27. 
Mass spectrometry has also been applied to gain insight into T-cell metabolism17,28,29.  
Nonetheless, currently there is no consensus regarding how to prepare non-adherent mammalian 
cell samples for metabolomics and even less guidance specifically for immune cells30,31.  This 
may explain why two of the above cited studies required approximately 3 x 107 T-cells per 
replicate to achieve their observed results. Others are aspiring to perform single-cell 
metabolomics on Aplysia californica neurons32, hinting that there may be room for improvement 
also for T-cells, provided the appropriate protocols and equipment.  In any metabolomics assay, 
the samples must be prepared in a reproducible manner that maintains intracellular metabolite 
integrity.  Hence, for T-cells the basic objectives are to rapidly quench metabolic activity and 
remove extracellular contaminating media metabolites by washing, before extracting the 
metabolites from the cells30,31,33,34. 
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In light of the growing interest in immune cell metabolism, we undertook this study with the goal 
of developing an extraction protocol specifically suited for human T-cells.  In some assays, 
sophisticated technologies and automation can help push the boundaries of low input and 
ease32,35,36. Our goal was to provide a simple and easily transferable protocol, while still 
improving economy in cellular input compared to previous studies17,28.  Although the general 
approach in previous studies has been to achieve the highest yields of certain subsets of 
metabolites, we preferred to take a step beyond that and to set the bar at reproducing known T-
cell biology to validate our method.  Antigen-naïve T-cells are known to undergo drastic 
metabolic changes upon immune-challenge. They shift away from a basal, catabolic metabolism 
that relies primarily on oxidative phosphorylation, to aerobic glycolysis and glutaminolysis in 
order to meet their anabolic and effector function requirements15,18,28,37.  There is also a growing 
appreciation of the role metabolism plays in T-cell fate and differentiation; with most knowledge 
centering around the balance between aerobic glycolysis, glutaminolysis and higher mTOR 
activity determining short-lived effector fates on one hand, and oxidative phosphorylation with 
consumption of alternative fuels such as fatty acids leading to regulatory cells and long-lived 
memory cells on the other18,22,29,37,38.  It has been demonstrated that activating the PD-1 signaling 
axis downregulates aerobic glycolysis16.  During the course of our study, it was published that 
PD-1 also reduces glutaminolysis and increases the reliance on fatty acid oxidation17.  Given our 
interest in how T-cell metabolism relates to immune checkpoint inhibition therapy, we 
questioned whether through an optimized metabolomics protocol we could confirm and augment 
what is known about the metabolic reprogramming induced in human T-cells by PD-L1:PD-1 
axis signaling.  
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CHAPTER 2 
Development of a T-cell metabolite extraction protocol 
Our goal was to develop a method that would balance easy transferability to other labs and 
reduced cellular input requirement, with the usual aims of rapid quenching of metabolism and 
elimination of contaminating extracellular metabolites.  For the latter two objectives, rapid 
filtration solutions of different levels of sophistication have been proposed for prokaryotic and 
eukaryotic cells35,36,39,40.  Early in our investigation we chose to evaluate a filter-based method 
originally applied to microbial extraction that did not require pumps and automation40, but 
despite experimenting with several filter types and sizes we found filter clogging to be an issue.    
This limitation and reports of suboptimal recovery of metabolites from filters30,41 led us to 
prioritize a centrifugation-based strategy.   
Thus, we sought to find a quenching and washing solution that would maintain cell integrity for 
the duration of our customary centrifugation protocol (4 min at 500 x G-force).  Some solutions 
used or formally tested in the past for metabolite extraction of non-adherent cells include 
phosphate buffered solution (PBS)  with human and murine T-cells17,28, 0.9% (w/v) NaCl30 or 
0.85% ammonium bicarbonate (AMBIC) in 60% methanol33 with Chinese hamster ovary cells 
(CHO), 0.3% ammonium acetate and ammonium formate with the Jurkat T-cell leukemia cell 
line31, and 5% mannitol with human leukemia cell lines42.  Although very short exposure to 
deionized water (~2s) appears feasible in certain contexts with adherent cells43, osmotic shock 
has been reported to result in leakage of solutes44.  Methanol exposure also was reported to 
compromise cell membrane integrity and cause leakage30,34,44.  We reasoned that microscopy 
could serve as a quick screening test to assess gross morphological changes with exposure to the 
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various wash solutions.  As expected, gross changes were not observed with isotonic salt 
solutions or 5% mannitol (Fig. 1a), however 150 mM ammonium acetate caused significant 
swelling of the cells and 60% methanol/AMBIC solution distorted the cells upon contact (Fig. 
1a).  The drastic changes induced by the methanol/AMBIC solution and the poor metabolic 
profiling results reported by others30,34 led us not to examine this approach further.   
To determine whether the swelling seen with ammonium acetate would have a negative impact 
on metabolite measurements, we exposed spontaneously immortalized mouse embryonic 
fibroblasts (MEF) to ammonium acetate or NaCl wash solutions and removed the solutions 
immediately after one swirl in the tissue culture dish, after 20 seconds, or after 60 seconds, 
taking advantage of the adherent nature of these cells.  Metabolite extraction was performed 
directly on the plate.  Principal component analysis of 137 identified metabolites showed that the 
variability of biological replicate measurements increased as a function of time with the 
ammonium acetate wash (Fig. 1b).  Loss of signal of the tricarboxylic acid cycle (TCA) 
metabolites has been suggested as a better indication of leakage than more highly charged 
phosphorylated metabolites33.  We found most TCA metabolite signals were decreased at 60 s 
with the ammonium acetate wash (Fig. 1c), a much shorter time-point than our 4 min point 
required in a centrifugation protocol.  On the contrary, the signal for citrate and aconitic acid was 
higher and increased as a function of time, as did the variability among replicates. The signal was 
more stable and consistent among replicates with the isotonic NaCl wash (Fig. 1d).  
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 Figure 1.  Meaningful metabolic changes can be profiled from immune cells with low 
cellular inputs using a mannitol wash solution. 
(a)  Light microscopy images show changes in cellular morphology with certain wash solutions.  
Jurkat cells were exposed to different wash solutions for the indicated time intervals.  The 
ammonium acetate iso-osmotic wash buffer provides little tonicity and causes considerable 
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swelling of the cells.  The ice-cold ammonium bicarbonate solution in 60% methanol causes cell 
changes on contact.  In contrast, such changes are not noted with the mannitol solution.  (b)  
Principal component analysis of 137 profiled metabolites demonstrates that the variance of 
intracellular metabolite measurements increases as a function of time when exposed to the 
ammonium acetate solution.  Spontaneously immortalized 3T3 mouse embryonic fibroblasts 
were exposed to a 0.9% NaCl or 150 mM ammonium acetate solutions for the indicated times.  
The ellipses were added for emphasis.  (c) The levels of the intracellular tricarboxylic acid cycle 
intermediates alpha-ketoglutarate, succinate, fumarate, and malate decrease with the 60 second 
ammonium acetate buffer exposure, suggestive of leakage from 3T3 cells.  (d) Levels of citrate 
and aconitic acid are relatively stable with the NaCl wash solution and thus not indicative of 
leakage.  (e)  Correlation of profiled metabolites between mannitol and NaCl wash solutions.  
Triplicates of 2 x 106 Jurkat cells per condition.  (f)  Correlation of metabolite measurements of 
two-fold serially diluted samples.  Values are corrected for the dilution factor.  The dashed lines 
represent a perfect correlation.  The solid colored lines are the best fit lines of the data.  (g)  
Schematic displaying the reduced flux of galactose derived intermediates ending with complete 
oxidation to CO2 compared to high glycolytic flux with glucose and production of lactate.  (h)  
Supernatant lactate levels of activated primary human T-cells in glucose- or galactose-containing 
culture medium.  Displayed are the summary results of three experiments, sampled from three 
replicate wells per condition (n = 9 vs. 9). 
 
We decided to consider further only isotonic solutions and compared NaCl to mannitol using 2 x 
106 Jurkat cells, as a model of suspension cells and human primary T-cells.  Measurements were 
highly correlated between samples processed with each wash buffer, with mannitol providing 
only a slight advantage in detecting metabolites with lower signal (Fig. 1e).  Furthermore, we 
tested the ability to detect two-fold changes in metabolites by performing serial dilution of the 
cellular inputs.  The correlation of observed values of the diluted samples, to the predicted values 
that were based on the top concentration, was similar for both washes (Fig. 1f).  Given similar 
performance with our platform, we chose mannitol for our subsequent experiments.  Mannitol 
has been used to reduce the ionic matrix and its effect on electrospray ionization and enhance 
performance of other technologies, such as capillary electrophoresis42,45–47, as an alternative to 
hypotonic methods32,48. 
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Ultimately, our goal was to compare equal cellular inputs of differently treated T-cells, which is 
different from serial dilution, where sample matrix is halved artificially and could have 
unpredictable effects related to ion suppression49,50.  Thus, as a control perturbation of 
metabolism, we substituted galactose for glucose in cell culture media, which is known to 
decrease glycolytic flux and force cells to respire18,51–53 (Fig. 1g).  We used 8.4 x 105 activated 
human T-cells per replicate, based on our serial dilution experiment.  Lactate production was 
suppressed when cells were grown in the galactose-containing medium (Fig. 1h).  The results of 
this experiment are displayed in Table 1. We detected higher levels of the Leloir pathway 
intermediates UDP-hexose and hexose-phosphate with galactose treatment.  Aspartic acid was 
also elevated, consistent with recent reports that intracellular aspartic acid levels increase as a 
result of respiration in proliferating cells54,55.  Glycolytic intermediates were higher in the glucose 
condition, as was UDP N-acetylglucosamine, which is reflective of higher available glucose 
pools for the hexosamine pathway56.  Thus, the findings fit expectations based on the literature. 
Compound fold change 
glucose vs. galactose 
p.value FDR pathway 
UDP-hexose -1.42 6.39 x 10-5 7.46 x 10-04 Leloir 
Hexose-phosphate -8.98 4.07 x 10-4 3.36 x 10-03 both 
Fructose-1,6-bisphosphate 9.22 8.37 x 10-7 2.34 x 10-05 glycolysis 
Glyceraldehyde-3-P 1437.38 9.12 x 10-4 4.91 x 10-03 glycolysis 
Dihydroxyacetone-P 583.69 6.54 x 10-3 2.41 x 10-02 glycolysis 
3-phosphoglycerate 2.75 4.90 x 10-4 3.61 x 10-03 glycolysis 
Phosphoenolpyruvate 1.24 7.23 x 10-1 8.04 x 10-01 glycolysis 
Pyruvate -1.52 4.44 x 10-1 5.92 x 10-01 glycolysis 
Lactate 44.66 2.41 x 10-6 3.97 x 10-05 glycolysis 
UDP N-acetylglucosamine 16.26 1.46 x 10-6 2.92 x 10-05 misc 
Aspartic Acid  -5.97 4.76 x 10-4 3.61 x 10-03 misc 
 
Table 1.  Intracellular metabolite level changes of activated human primary T-cells in 
culture medium containing Glucose vs. Galactose. 
Summary of three experiments with each condition performed in triplicate.   
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CHAPTER 3 
T-cell activation and checkpoint system 
Having established the parameters needed to detect expected metabolic changes from a known 
nutrient restriction manoeuver in human primary T-cells, we were next interested in examining 
metabolic changes imposed by negative signaling through the programmed cell death 1 receptor 
(PDCD1/PD-1).  There are several available options to activate T-cells in vitro.  These include 
superantigen toxins, mitogens, phorbol esters, activating antibodies, and artificial antigen 
presentation57,58.  Activating antibodies, immobilized to culture vessel surfaces or paramagnetic 
beads, have become popular due to their ease of use compared to cellular antigen presentation 
systems and improved functional outcomes compared to mitogens58,59.  The optimization focus 
has been on maximal activation and expansion or maximal cytokine production, in part driven by 
adoptive cell transfer efforts60,61, as higher numbers of transferred cells have correlated with 
better outcomes and minimum thresholds for transfer are commonly used6,62. There are reports of 
the use of such antibodies in conjunction with recombinant human PD-L1 peptide, but they differ 
in their recommendation of the delivery method of the inhibitory ligand63–66.  None of these 
methods has used a cell-based antigen presentation system as a benchmark of physiologic 
activation. 
We adapted a plate-based activation system67 that used antibodies for artificial co-stimulation of 
T-cells through CD3 and CD28, and either Fc fragment of IgG as control or a recombinant 
human protein ligand of PD-1 conjugated to Fc (rhPD-L1.Fc) for concurrent T-cell inhibition 
(Fig. 2a).  Treatment of peripheral blood mononuclear cells with a clinical-grade adoptive cell 
transfer expansion protocol61, caused increased cell-surface expression of PD-1 (data not shown).   
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The conditions of this protocol favor expansion of T-cells over other peripheral blood 
mononuclear cells (PBMCs), but we also incorporated an immunomagnetic T-cell isolation step 
prior to treatment.  After isolation on day 7, T-cells were placed in the treatment plates, as 
depicted in Figure 2a. 
 
Figure 2.  Recombinant human PD-L1 efficiently inhibits T-cells activated by antibody-
based stimulation. 
(a)  Schematic representation of T-cell treatment prior to metabolite extraction.  PBMC are 
expanded using a clinical grade adoptive cell transfer protocol that leads to upregulation of PD-1 
receptor on the surface of T-cells.  Isolated T-cells are then seeded in plates with anti-CD3 and 
anti-CD28 antibodies with or without recombinant human PD-L1 (rhPD-L1).  (b)  IFN gamma 
ELISA of 24 hour supernatants.  T-cells bearing an exogenously expressed MART-1 specific T-
cell receptor (F5 TCR) were co-cultured with M202 melanoma cells that present MART-1 via 
HLA-A2.1, M238 cells that do not, K562 cells with exogenous expression of HLA-A2.1 pulsed 
with MART-126-35 peptide, or stimulated with anti-CD3 and anti-CD28 antibodies without target 
cells. Importantly, anti-CD3 and anti-CD28 antibody-based stimulation activates T cells to 
comparable levels as does cell-based melanoma antogen presentation. 
 
To simulate known pathophysiology and ensure that the rhPD-L1.Fc could inhibit in-vitro 
antibody-based stimulation that was relevant to cell-based activation, we made use of transgenic 
T-cell receptor-bearing effector cells (F5 TCR) in co-culture with melanoma or K562 
erythroleukemia cell lines presenting cognate MART-1 antigen68.  We titrated antibody-based 
activation to produce similar levels of interferon gamma (IFNg) compared to cell-based 
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activation, and we demonstrated that the ligand effectively inhibited this response (Fig. 2b), thus 
generating a system to study immune activation and inhibition by PD-L1.  
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CHAPTER 4 
PD-L1 checkpoint induced metabolic changes 
With our newly established extraction method, we interrogated metabolic changes in T-cells 
caused by negative PD-L1:PD-1 axis signaling using liquid chromatography-mass spectrometry 
(LC-MS).  After 72 hours of treatment, an overview of the 146 adequately measured intracellular 
metabolites of our 155 metabolite panel showed most to be decreased as a result of rhPD-L1.Fc 
treatment (Fig. 3a).  The glycolysis pathway metabolites were significantly decreased compared 
to the Fc control (Fig. 3b) consistent with reports of a shift away from aerobic glycolysis16,17.  
Metabolic profiling of the culture medium showed that rhPD-L1.Fc-treated cells produced 
significantly less lactate and alanine in 24 hours and consumed less glucose, glutamine and 
serine (Fig. 3c), consistent with a less activated, less anabolic state, and a shift away from 
aerobic glycolysis and glutaminolysis17,28.  Inhibited cells had higher levels of the pyrimidine 
nucleoside precursor aspartate and lower levels of nucleoside phosphates (Fig. 3d). 
To further investigate these changes we performed [U-13C] glucose tracer experiments.  By 
analyzing the steady-state isotopomer distributions of metabolites, one can gain insight into 
relative pathway activities, particularly for non-linear pathways with multiple possible 
contributing pathways, such as the TCA cycle69.  In the inhibited condition, we found fewer 
glucose derived 2-carbon units entering via pyruvate resulting in less citrate M2, suggesting an 
alternate source of acetyl-CoA (Fig. 4a).  Less unlabeled a-ketoglutarate M0 suggested fewer 
unlabeled carbons from glutaminolysis.  Succinate M0 fractional labeling was reversed, 
suggesting more unlabeled carbons entering at succinyl-CoA, possibly from the terminal 3-
carbon units of odd chain fatty acids or branched chain amino acids (BCAA).  We did not  
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 Figure 3.  Relative levels of intracellular and supernatant metabolites in activated vs. PD-
L1-inhibited T-cells. 
(a)  Overview of all profiled intracellular metabolites as measured by mass spectrometry.  
Positive values indicate higher levels in the activated condition (Fc).  Dotted lines represent a 
two-fold change on the log2 scale.  (b)  Glycolysis pathway intracellular metabolites are higher in 
activated cells.  (c)  Compared to PD-L1 treated cells, more lactate and alanine are produced, and 
more glucose, glutamine and serine are consumed by activated T-cells.  (d)  Nucleoside 
phosphates are increased and aspartic acid levels are decreased in activated T-cells.  FDR:  false 
discovery rate.  †:  FDR > 0.05.  All values represent four experiments with triplicates of each 
condition and have FDR < 0.05 unless indicated otherwise.  Values are capped at 100-fold in 
panel a. 
 
measure oxaloacetate directly, but we determined that aspartate was not consumed from the 
media in either condition and thus its labeling pattern was interpreted to be in equilibrium with 
oxaloacetate based on past studies69.  Hence, higher aspartate M3 indicated pyruvate 
carboxylation, three labeled carbons coming from pyruvate and one unlabeled carbon from 
CO269–71.  Despite similar levels of ribose-5-phosphate labeling (Fig. 4b) and higher total aspartic 
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acid labeling, there were significant decreases in UMP M5 and UMP M6-7, reflecting lack of 
incorporation of labeled carbons from ribose-5-P and aspartic acid respectively.  This labeling 
pattern was apparent in the majority of the profiled nucleoside phosphates (data not shown).  
Taken as a whole, these changes suggest a switch from aerobic glycolysis and glutaminolysis to 
alternative contributing pathways, such as fatty acid beta oxidation and BCAA catabolism, and is 
consistent with a substantial reduction in the synthesis of nucleosides de novo (Fig. 4c). 
 
Figure 4.  [U-13C] glucose tracing shows differences in metabolite contribution to the TCA 
cycle and decreased nucleoside phosphate synthesis upon PD-L1 inhibition. 
(a)  Select isotopomers of TCA metabolites used to infer metabolite contributions to the TCA 
cycle, expressed as the percentage of all isotopomers detected for the respective compounds.  M0: 
unlabeled.  M2:  Two heavy carbons from glucose.  M3:  Three heavy carbons from glucose.  (b)  
Select isotopomers of uridine monophosphate and ribose-5-phosphate that represent the 
contribution of fully labeled ribose-5-phosphate (UMP M5) plus partially labeled aspartic acid 
(UMP M6-7).  (c)  Schematic of inferred relative metabolic pathway contributions to the TCA 
cycle in PD-L1 treated cells.  Thick arrows represent more relative contribution of a pathway in 
the PD-L1 treated cells compared to the Fc control. 
To our knowledge, a shutdown in nucleoside phosphate de novo biosynthesis as a result of PD-1 
ligation has not been previously documented.  De novo pyrimidine and purine biosynthesis is 
required for cell cycle progression and proliferation of activated T-cells72.  We questioned 
whether this negative regulation could be an early event and a potential early metabolic 
checkpoint15.  If so, we wondered whether circumventing the block in nucleoside phosphate 
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synthesis would rescue the proliferation defect that accompanies PD-L1:PD-1 axis signaling73.  
Thus, we assayed metabolites at an earlier 24 hour time-point.  Our findings were again 
consistent with reduced glycolysis and glutaminolysis, but overall changes were more modest.  
Among relative level changes caused by rhPD-L1.Fc treatment with an FDR < 0.05, we found 
decreased ribose-5-P and UMP, and an increased pool of aspartic acid (Fig. 5a). A tracer 
experiment with [U-13C] glucose showed that the inhibited cells incorporated less 13C from 
ribose-5-P.  At this early timepoint, the fold reduction was larger for pyrimidines than purines 
(Fig. 5b). 
The mechanistic target of rapamycin complex 1 (mTORC1) has been shown to regulate 
nucleoside phosphate synthesis.  The first committed step in pyrimidine synthesis is controlled 
by an activating phosphorylation of the trifunctional enzyme carbamoyl-phosphate synthetase 2, 
aspartate transcarbamylase, and dihydroorotase (CAD) by mTORC174.  Purine synthesis is 
induced by mTORC1 through transcriptional upregulation of genes, including 
methylenetetrahydrofolate dehydrogenase 2 (MTHFD2)75.  By western blotting, we probed 
phosphorylation sites on downstream targets of mTORC1, including CAD, and found decreased 
activity with rhPD-L1 treatment (Fig. 5c).  In certain cellular contexts, isolated deficiency of 
nucleoside phosphate synthesis can be rescued by providing substrates downstream of the level 
of the block, including nucleosides themselves74–76.  Thus, we supplemented rhPD-L1-treated T-
cells with a cocktail of nucleosides (cytidine, guanosine, uridine, adenosine, thymidine; 
Embryomax®, Millipore # ES-008-D) of varied concentration and measured the effect on cell 
number after 48 hours of treatment.  We were not able to document a consistent dose-dependent 
rescue effect on cell number by assaying total DNA fluorescence, nor by reductive capacity (Fig. 
5d). 
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 Figure 5.  Nucleoside phosphate synthesis deficiency is an early event with PD-L1 
inhibition, particularly for pyrimidines. 
(a)  Relative levels of nucleoside phosphates and aspartic acid at 24 hours of treatment.  (b)  
Statistically significantly changing 13C incorporation into nucleoside phosphates from [U-13C] 
glucose.  All measurements have a FDR<0.05 but the fold-reduction is larger for pyrimidines 
than for purines.  (c)  Western blot of phosphorylation status of mTORC1 targets.  T-cells were 
treated for 48 hours as indicated.  Jurkat cells were treated for 2 hours.  PHA: 
phytohemagglutinin 5 µg/mL.  Rapamycin dose:  20 nM. (d)  Alamar blue resarufin fluorescence 
assay of Fc and PD-L1 treated T-cells with or without nucleoside cocktail supplementation for 
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48 hours. (e)  DNA fluorescence assay of Fc and PD-L1 treated T-cells with or without 
nucleoside cocktail supplementation for 48 hours.  
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CHAPTER 5 
Discussion 
The use of a simple centrifugation-based extraction protocol specifically optimized for T-cells 
enabled us to measure relative level changes of metabolites and perform 13C label tracing of 
metabolic pathways using 8.4 x 105 cells per replicate, a more than 35-fold reduction in cell input 
requirement compared to 3 x 10 7 cells used in previous studies17,28.  Our data recapitulated what 
is known about mammalian cells forced to respire while growing with galactose as their carbon 
source18,51–53.  We generated a system for studying T-cell activation and inhibition, and we were 
able to clearly demonstrate that PD-L1 treatment decreases glycolytic flux and glutaminolysis, in 
line with previous studies16,17.  We extended what is known about PD-L1 induced metabolic 
reprogramming in human T-cells by giving a detailed picture of altered TCA cycle pathway 
contributions and demonstrating reduced de novo nucleoside phosphate synthesis. 
To our knowledge, the negative effects of ammonium acetate on metabolite measurements have 
not previously been reported, whereas the poor yields with methanol wash solutions have30,34,44.   
The permeability of mammalian cells to ammonium salts of weak acids is known, given that they 
have been studied as cell-penetrating cryopreservation agents77–79.  Thus, the swelling of cells 
with prolonged exposure could have been predicted.  A study with primary focus on lipidomics 
in Jurkat cells came to the conclusion that ammonium acetate is appropriate for human 
mammalian non-adherent cell metabolomics31.  A study using ammonium acetate as a wash 
solution for secondary ion mass spectrometry (SIMS) found no significant effect on viability, 
however the wash solution was “added and immediately removed” and optimization parameters 
would be different than for LC-MS experiments80.  We found that 150 mM ammonium acetate is 
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not an isotonic solution, consistent with its ability to permeate cell membranes, and in our assay 
this led to more variable results.  We were able to improve the consistency of our measurements 
by using mannitol (Fig. 1c).  This highlights that in developing an extraction protocol, one needs 
to take into consideration many factors and to tailor the method to the particular application, 
while making sure to test prior reports for applicability and reproducibility in the new context.   
It follows from above that our extraction protocol may have certain limitations if applied 
differently.  In the case of SIMS imaging, washing with a sucrose solution left an interfering 
residue80, and it is likely that mannitol would do the same.  The most attractive property of 
ammonium salts of weak acids is their volatility.  Osmotic effects are less drastic than with 
deionized water80 (and data not shown) and the ions will evaporate with drying, thus eliminating 
ion suppression. Thus, ammonium salts possibly remain preferable to mannitol for very short 
exposure washes, such as with adherent cells.  Even at ice-cold temperatures, certain very low 
abundance metabolites with high conversion rates can still be metabolized in the 4 min it takes to 
complete our wash and thus go undetected.  For profiling of such metabolites, a fast filtration 
method may be necessary.  Our metabolite profiling parameters allowed us to sufficiently 
demonstrate changes in cells forced to respire with galactose, or treated for 24-72 hours with 
rhPD-L1.Fc but adjustments may be required to profile more subtle phenotypes. 
Treatment of activated T-cells with PD-L1 reduces aerobic glycolysis and glutaminolysis, and 
cells use beta oxidation of fatty acids as an alternative fuel source16,17.  Our tracer experiments 
are consistent with more unlabeled acetyl groups entering the TCA cycle from fatty acid 
oxidation and the conversion of other substrates.  This would be expected to inhibit the pyruvate 
dehydrogenase complex and it would explain why we see carboxylation of pyruvate to 
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oxaloacetate70.  Our data does not corroborate that PD-1 signaling impairs branched chain amino 
acid oxidation17.  We don’t see the same changes in relative levels of these amino acids as 
previously reported.  The contribution of odd chain fatty acids to succinyl-CoA is only the 
terminal 3 carbons of the chain, all others entering through acetyl-CoA.  Thus, it is probable that 
the large influx of unlabeled carbons at succinyl-CoA represents other substrates, among which 
isoleucine and valine are candidates.  Labeled BCAA studies would be necessary to confirm this.  
We found higher relative levels of aspartate in PD-L1 treated cells, but relative levels of a 
metabolite in isolation are hard to interpret, as either increased production or reduced 
consumption could be the cause.  Distinguishing between the two is difficult without the 
appropriate labeled tracer study69.  Two groups have shown that increased function of the 
electron transport chain results in higher production of aspartate54,55.  However, although PD-L1-
treated cells rely more on fatty acid beta oxidation, it has been shown that their net basal oxygen 
consumption rate is decreased17.  We see a decrease in de novo nucleoside phosphate 
biosynthesis, making it more compelling to hypothesize that less aspartate is being consumed to 
produce pyrimidines. 
It was reported that mTORC1 controls pyrimidine biosynthesis via signaling-based mechanisms 
involving phosphorylation-based activation of CAD74.  mTORC1 also controls purine 
biosynthesis, but typically on a longer time-frame through transcriptional regulation75.  
Nucleoside phosphate de novo synthesis is a requirement for T-cells to proliferate72 and thus 
represents a metabolic checkpoint.  We found that decreased de novo synthesis of nucleoside 
phosphates is present as early as 24 hours during treatment, is more pronounced in pyrimidines at 
this time point, but is substantially seen for both pyrimidines and purines by 72 hours. This 
kinetic pattern is consistent with the typically quicker signaling-based regulation of pyrimidine 
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synthesis, in comparison to the transcription-based regulation of purine synthesis summarized 
above.  We also observed that phosphorylation of mTORC1 targets was decreased.  In our 
experiments, we were not able to rescue proliferation in PD-L1 treated cells by providing 
exogenous nucleosides.  It is possible that a different dosing scheme with an optimized balance 
of each nucleoside may have resulted in an observable rescue.  But even if the requirements of 
import and phosphorylation of nucleosides were met, an inability to rescue would not be entirely 
unexpected, as mTOR controls many other cellular processes81.  Additionally, PD-L1:PD-1 
negative signaling is known to engage cell cycle checkpoints82–84 that are attributed to non-
metabolic mechanisms. 
In conclusion, we have developed an easily transferable and low-input metabolite extraction 
protocol for human T-cells and have used it to show that in addition to its known metabolic 
effects, PD-L1 inhibits nucleoside phosphate de novo biosynthesis.  Our data demonstrate that 
multiple metabolite levels are decreased with inhibitory signaling, suggesting broad metabolic 
regulation.  This would be expected with downregulation of mTOR signaling, often referred to as 
a “master regulator of metabolism”.  It would also suggest that correcting isolated metabolic 
pathway defects may not be sufficient to restore T-cell function without significant concurrent 
manipulation of cell signaling, as we saw with our nucleoside supplementation experiment.  The 
same does not necessarily hold true for augmenting immunotherapy.  A recent metabolomics 
study profiled changes of activated naïve cells and showed a role for arginine metabolism in 
enhancing T-cell survival and anti-tumor activity85 and a follow up study by another group 
showed that arginine supplementation enhanced the efficacy of anti-PD-L1 treatment in a mouse 
model of osteosarcoma86.  Thus, further mining of our existing metabolomics data combined 
with other omics data85 would be promising to generate hypotheses regarding beneficial 
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metabolic manoeuvers that could be tested with adoptive cell transfer models.  Our activation 
system can be easily adapted to interrogate the metabolic effects of drugs, cytokines, stimulatory 
and inhibiting interactions that may be of interest to individual immunometabolism labs.  It is 
interesting to speculate what we can be taught about T-cell memory with our existing data and a 
combined omics approach, given that oxygen consumption profiles of PD-L1 treated human T-
cells and IL-15 memory-polarized murine cells both display an increase in spare respiratory 
capacity17,22 and that PD-L1 mediated exhaustion can be reversed, at least to a certain extent, 
with checkpoint inhibition therapy87.  
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CHAPTER 6 
Methods 
Cell lines and culture. 
Human peripheral blood mononuclear cells, Jurkat cells, M202 and M238 melanoma cells were 
grown in RPMI 1640 with glutamine supplemented with 10% fetal calf serum and 1% SPF 
antibiotic.  Immortalized mouse embryonic fibroblasts were cultured in DMEM.  Peripheral 
blood mononuclear cells (PBMCs), Jurkat cells and melanoma cells were provided by Dr Antoni 
Ribas.  MEFs were immortalized in our lab as previously described88. 
Timed exposure to wash solutions - Jurkat cell morphology. 
Jurkat T-cell leukemia cells were seeded into poly-D-Lysine coated 96-well plates at 2 x 105 
cells per well in cell culture medium and centrifuged at 30 x G-force for 1 minute with the brake 
off. The plate was placed on a Nikon eclipse Ti microscope stage.  One well at a time, the cell 
culture medium was aspirated and replaced with the indicated ice-cold wash solutions.  Images 
were acquired at the indicated times. 
Wash solution time-course with adherent cells for metabolomics. 
Spontaneously immortalized mouse embryonic fibroblasts were seeded in triplicate at 2.5 x 105 
cells per 9 cm2 and incubated overnight to allow for attachment.  The culture medium was 
aspirated one replicate at a time and washed with either ice-cold 150 mM ammonium acetate 
aqueous solution or 0.9% (w/v) NaCl solution.  The wash solution was aspirated either 
immediately, at 20 seconds, or at 60 seconds.  The plate was placed on ice.  Metabolites were 
extracted directly from the plate with 1 mL ice-cold 80% (v/v) methanol/H2O.  The cells were 
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scraped and the content of the plate transferred to a 1.5 mL plastic disposable centrifuge tube and 
placed first on dry ice and then into a -80⁰ freezer until further processing. 
Serial dilution of Jurkat cells and centrifugation-based extraction. 
Jurkat cells were serially two-fold diluted to give 2 x 106, 1 x 106, and 0.5 x 106 cells per 
replicate.  The cells were separated from culture medium by centrifugation at 500 x G-force for 4 
min followed by aspiration.  Mannitol or NaCl ice cold solutions of 1 mL volume were added 
and followed by a second centrifugation using the same parameters at 4⁰ C.  After aspirating the 
wash solution the cells were immediately extracted using 250 µL ice-cold methanol, followed by 
250 µL diH2O, and then 250 µL chloroform, vortexing briefly in between steps.  The mixture 
was centrifuged at top speed for 5 min at 4⁰ C and the upper aqueous phase was collected into a 
glass chromatography vial and stored at -80⁰ C until further processing as described below for T-
cell metabolomics. 
Carbon source experiments. 
Glucose-free RPMI 1640 (ThermoFisher #11879020) was supplemented with 10 mM glucose or 
galactose, 10% dialyzed fetal calf serum and 1% SPF.  Cells were seeded in activating conditions 
in 12-well plates at 8.4 x 105 cells per 500 µL culture medium in triplicate for each carbon source.  
After 24 hours, media was collected and intracellular metabolites extracted as per the T-cell 
metabolite extraction protocol below. 
T-cell directed expansion of peripheral blood mononuclear cells (PBMCs). 
Human PBMCs were expanded toward the T-cell lineage as previously described61 with 
modifications.  Cryopreserved cells at 1 x 107 cells/mL were thawed and diluted in RPMI 
containing 10% fetal calf serum and 1% penicillin, streptomycin and amphotericin by adding 
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1mL cells to 5mL warm media, followed by centrifugation at 500 xG-force for 4 min and 
replacement of supernatant with 1mL fresh medium containing DNAse 227 U/mL for 45 min at 
37⁰ C without disturbing the pellet.  The cells were resuspended with 9 mL medium and a 10 µL 
aliquot was counted before another round of centrifugation and placement in fresh medium in 
tissue culture flasks at 7 x 105 cells/mL.  The cells were incubated for 48 hours with 50 ng/mL 
OKT3 anti-CD3 antibody in solution (OKT3, Miltenyi Biotec, Auburn, CA) and 300 IU/mL IL-2.  
The medium was then replaced with 300 IU/mL IL-2-containing medium for the duration of 
expansion.  Medium acidity was monitored and fresh medium added to maintain a concentration 
of 7 x 105 cells/mL approximately every two days. 
T-cell activation and treatment with PD-L1 
Treatment plates were coated at 4⁰ C overnight with  1 µg/mL anti-CD3 antibody (BD 
biosciences 555329) and 1.5 µM human IgG Fc fragment (Jackson Immunoresearch #009-000-
008) or 1.5 µM rhPD-L1.Fc (Sino Biological #10084-H02H) in 1.2 mL PBS per well of a 12-
well non-tissue culture treated plate (Corning #351143).  The antibody-coated plate was then 
washed twice with 2 mL PBS and blocked for 1 hour at room temperature with 1.5 mL human 
serum albumin 2.5% in PBS, followed by two more washes with PBS.  T-cells expanded for 7 
days were isolated by use of an immunomagnetic negative enrichment kit (ThermoFisher 
#11344D) and seeded in triplicate wells at 8.4 x 105cells in 1.2 mL glucose-free RPMI 
(ThermoFisher #11879020) treatment medium supplemented with 10 mM [U-13C] glucose 
(Cambridge Isotope Laboratories #CLM-1396-PK), 10% dialyzed fetal calf serum, 1% SPF, and 
1 µg/mL anti-CD28 antibody (BD biosciences # 555725).  For 72 hour treatments, the treatment 
medium was refreshed 24 hours prior to harvest. 
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T-cell metabolite extraction protocol 
Treated T-cells were harvested into microcentrifuge tubes and centrifuged at 500 x G-force for 4 
min.  The medium was collected into separate tubes and placed on dry ice and then into -80⁰ C 
until further processing.  Ice-cold 5.4% mannitol wash solution was added, 1 mL to each pellet 
and centrifuged with the same parameters at 4⁰ C.  All subsequent steps are performed on ice 
with all solutions ice-cold.  The wash solution was removed and 250 µL methanol added, then 
250 µL water, and finally 250 µL chloroform, vortexing briefly in between steps.  The mixture 
was centrifuged at 16,000 x G-force for 5 min.  The top polar phase was collected into glass 
chromatography vials and stored at -80⁰ C until further processing.  The tube was tilted carefully 
to expose the non-polar phase which was collected separately, but not included in this analysis.  
The interphase was retained for later protein quantitation with a BCA assay kit (ThermoFisher 
#23225) per manufacturer microplate protocol.  The polar phase, 20 µL of the supernatants, and 
three mock extracted controls per run (polar phase of extraction mixture without cells) were 
evaporated with an EZ2 Elite centrifugal evaporator for 80 min on HPLC setting with 30⁰ C 
maximum temperature.  The samples were block randomized and stored at -80⁰ C prior to 
recovery and submission to mass spectrometry. 
Liquid chromatography and mass spectrometry 
Metabolites were recovered in 50 μL 70% ACN and 5 μL of this solution used for mass 
spectrometer-based analysis performed on a Q Exactive (Thermo Scientific) coupled to an 
UltiMate 3000RSLC (Thermo Scientific) UHPLC system. Mobile phase A was 5 mM NH4AcO, 
pH 9.9, B was ACN, and the separation achieved on a Luna 3u NH2 100A (150 × 2.0 mm) 
(Phenomenex) column. The flow was kept at 200 μL/min, and the gradient was from 15% A to 
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95% A in 18 min, followed by an isocratic step for 9 min and re-equilibration for 7 min. 
Metabolites we detected and relatively quantified as area under the curve (AUC) based on 
retention time and accurate mass (≤ 3 p.p.m.) using TraceFinder 3.3 (Thermo Scientific) 
software. 
Co-culture of transgenic T-cells with melanoma and K562 targets. 
Production of transgenic MART-1 specific TCR bearing T-cells was previously described68. 
Twenty-four hour IFNg secretion into the supernatant was assayed by ELISA (ThermoFisher 
#88-7316-77).  Antibody stimulation is described in the T-cell activation section. 
Western blotting 
Primary antibodies used were Phospho-CAD (Ser1859) Antibody #12662, Phospho-p70 S6 
Kinase (Thr389) (108D2) Rabbit mAb #9234, Phospho-4E-BP1 (Ser65) (174A9) Rabbit mAb 
#9456, and β-Actin (D6A8) Rabbit mAb #8457 from Cell Signaling.  
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